The Role of Iron in Calciphylaxis-A Current Review

Area of Science:

• Nephrology
• Vascular Biology
• Pathophysiology

Background:

• Calcific uraemic arteriolopathy (CUA), or calciphylaxis, is a rare, severe condition affecting end-stage renal disease (ESRD) patients.
• Iron supplementation, used for anemia in ESRD, is a suspected risk factor for CUA pathogenesis.
• Existing data on iron's role in CUA is inconclusive, with some studies showing no difference in incidence between iron dosage groups.

Purpose of the Study:

• To evaluate the role of iron supplementation in the pathogenesis of calcific uraemic arteriolopathy.
• To assess the evidence linking cumulative iron exposure to CUA incidence in ESRD patients.

Main Methods:

• Review of observational studies and clinical trial data regarding iron supplementation and CUA.
• Analysis of postulated mechanisms involving vascular cell adhesion molecules and oxidative stress.

Main Results:

• Observational studies suggest a potential role for iron in CUA pathogenesis, possibly via inflammation and vascular calcification.
• However, a pivotal trial found no difference in CUA incidence between low-dose and high-dose iron treatment arms.
• A direct correlation between cumulative iron exposure and CUA incidence is not clearly established in the literature.

Conclusions:

• Despite theoretical links, current evidence does not demonstrate a clear correlation between iron exposure and CUA incidence.
• There is insufficient evidence to recommend reducing or stopping iron supplementation in ESRD patients who develop CUA.